Drug Profile
Research programme: Gram-positive infection therapeutics - ContraFect
Alternative Names: CF 302; CF 303; CF 304; CF 305; CF 306; CF-307; CF-308; CF-309; Direct lytic agents - ContraFect; Gram-positive lysins - ContrafectLatest Information Update: 25 Apr 2024
Price :
$50
*
At a glance
- Originator Rockefeller University
- Developer ContraFect
- Class Antibacterials; Endolysins; Enzymes; Recombinant proteins
- Mechanism of Action Cell membrane inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anthrax; Enterococcal infections; Pneumococcal infections; Streptococcal infections
Most Recent Events
- 04 Dec 2023 Discontinued for Anthrax in USA (unspecified route) as ContraFect filed for voluntary bankruptcy under chapter 11 of the US Bankruptcy code
- 04 Dec 2023 Discontinued for Enterococcal infections in USA (unspecified route) as ContraFect filed for voluntary bankruptcy under chapter 11 of the US Bankruptcy code
- 04 Dec 2023 Discontinued for Pneumococcal infections in USA (unspecified route) as ContraFect filed for voluntary bankruptcy under chapter 11 of the US Bankruptcy code